Andere talen Medexus Pharmaceuticals Inc.

Aandelen

MDP

CA58410Q2036

Beurs gesloten - Toronto S.E. Andere beurzen 21:57:29 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,79 ^CAD	+1,13%		-6,77%	-27,53%

26/03	Medexus Pharmaceuticals kondigt aan dat de US Food and Drug Administration haar aanvullende Biologics License Application voor IXINITY(R) goedkeurt	CI
09/02	MEDEXUS PHARMACEUTICALS INC. : Stifel GMP bevestigt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada	01/05
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	02/04
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients	27/03
Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	26/03
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients	26/03
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results	08/02
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results	08/02
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Medexus Announces Fiscal Q3 2024 Results	07/02
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak	07/02
Medexus Schedules Third Fiscal Quarter 2024 Conference Call	30/01
Medexus Pharmaceuticals - Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	09/01
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine	08/01
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections	08/01
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	08/01
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million	08/11
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11
Medexus Schedules Second Fiscal Quarter 2024 Conference Call	01/11
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering	17-10-23
Canadian Investment Regulatory Organization Trading Halt - MDP.DB	16-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Medexus Pharmaceuticals Inc.

Aandelen

MDP

CA58410Q2036

Andere talen

Filters